Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits

We herein outline the usefulness of drug-like screening hits. As for lead-like hits it is of pivotal importance to have a detailed profile with experimental data prior to initiating costly and resource-intense lead optimization programs. Drug-like and lead-like hits derived from HTS campaigns provid...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2006-02, Vol.11 (3-4), p.175-180
Main Authors: Wunberg, Tobias, Hendrix, Martin, Hillisch, Alexander, Lobell, Mario, Meier, Heinrich, Schmeck, Carsten, Wild, Hanno, Hinzen, Berthold
Format: Article
Language:English
Subjects:
ADME-Tox
Administration, Oral
Biological and medical sciences
Drug Design
General pharmacology
hit-to-lead process
hits
HTS
leads
Medical sciences
Pharmaceutical technology. Pharmaceutical industry
Pharmacokinetics
Pharmacology. Drug treatments
Toxicology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We herein outline the usefulness of drug-like screening hits. As for lead-like hits it is of pivotal importance to have a detailed profile with experimental data prior to initiating costly and resource-intense lead optimization programs. Drug-like and lead-like hits derived from HTS campaigns provide good starting points for lead optimization. However, too strong emphasis on potency as hit-selection parameter might hamper the success of such projects. A detailed absorption, distribution, metabolism, excretion and toxicology (ADME–Tox) profiling is needed to help identify hits with a minimum number of (known) liabilities. This is particularly true for drug-like hits. Herein, we describe how to break down large numbers of screening hits and we provide a comprehensive overview of the strengths and weaknesses for each structural class. The overall profile (e.g. ligand efficiency, selectivity and ADME–Tox) is the distinctive feature that will define the priority for follow-up.
ISSN:1359-6446
1878-5832
DOI:10.1016/S1359-6446(05)03700-1